These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND HIF1A, Q16665, 3091, ENSG00000100644, MOP1, HIF1-ALPHA, PASD8, HIF-1alpha
238 results:

  • 1. Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia.
    Liu S; Xu M; Yang Z; Li Y; Wu D; Tang X
    Eur J Med Res; 2024 Sep; 29(1):475. PubMed ID: 39343915
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Aberrant HIF1- α and SIX-1 Expression is Associated with Poor Prognosis in Acute Myeloid leukemia Patients with Isocitrate Dehydrogenase 1 Mutations.
    Ali T; Usman R; Shah SA; Parvez A; Anwar S; Muneer Z; Saeed M
    Cancer Control; 2024; 31():10732748241271714. PubMed ID: 39110525
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The Role of PTEN in Chemoresistance Mediated by the HIF-1α/YY1 Axis in Pediatric Acute Lymphoblastic leukemia.
    Antonio-Andres G; Morales-Martinez M; Jimenez-Hernandez E; Huerta-Yepez S
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063014
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Anti-cancer potential of casein and its derivatives: novel strategies for cancer treatment.
    Romero-Trejo D; Aguiñiga-Sanchez I; Ledesma-Martínez E; Weiss-Steider B; Sierra-Mondragón E; Santiago-Osorio E
    Med Oncol; 2024 Jul; 41(8):200. PubMed ID: 38990440
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Bioengineered niches that recreate physiological extracellular matrix organisation to support long-term haematopoietic stem cells.
    Donnelly H; Ross E; Xiao Y; Hermantara R; Taqi AF; Doherty-Boyd WS; Cassels J; Tsimbouri PM; Dunn KM; Hay J; Cheng A; Meek RMD; Jain N; West C; Wheadon H; Michie AM; Peault B; West AG; Salmeron-Sanchez M; Dalby MJ
    Nat Commun; 2024 Jul; 15(1):5791. PubMed ID: 38987295
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2).
    Nayarisseri A; Bandaru S; Khan A; Sharma K; Bhrdwaj A; Kaur M; Ghosh D; Chopra I; Panicker A; Kumar A; Saravanan P; Belapurkar P; Mendonça Junior FJB; Singh SK
    Adv Protein Chem Struct Biol; 2024; 141():223-253. PubMed ID: 38960475
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Placental apoptosis increased by hypoxia inducible factor-1 stabilization is counteracted by leptin†.
    de Dios N; Riedel R; Schanton M; Balestrini P; Pérez L; Pérez-Pérez A; Etcheverry T; Casale R; Farina M; Sánchez-Margalet V; Maymó J; Varone C
    Biol Reprod; 2024 Sep; 111(3):708-722. PubMed ID: 38924703
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations.
    Tawfik HO; Mousa MHA; Zaky MY; El-Dessouki AM; Sharaky M; Abdullah O; El-Hamamsy MH; Al-Karmalawy AA
    Bioorg Chem; 2024 Aug; 149():107483. PubMed ID: 38805913
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in leukemia.
    Pandey S; Singh R; Habib N; Tripathi RM; Kushwaha R; Mahdi AA
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1121-1134. PubMed ID: 38679971
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Effects of BMAL2 on Aerobic Glycolysis and Cell Proliferation in Acute Myeloid leukemia Cells].
    Jia WJ; Mu J; Cui WJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):402-408. PubMed ID: 38660843
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia.
    Lawson H; Holt-Martyn JP; Dembitz V; Kabayama Y; Wang LM; Bellani A; Atwal S; Saffoon N; Durko J; van de Lagemaat LN; De Pace AL; Tumber A; Corner T; Salah E; Arndt C; Brewitz L; Bowen M; Dubusse L; George D; Allen L; Guitart AV; Fung TK; So CWE; Schwaller J; Gallipoli P; O'Carroll D; Schofield CJ; Kranc KR
    Nat Cancer; 2024 Jun; 5(6):916-937. PubMed ID: 38637657
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells.
    Yadav AK; Wang S; Shin YM; Jang BC
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474118
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. HIF-1α/m
    Cong X; Li X; Xu K; Yin L; Liang G; Sun R; Pu Y; Zhang J
    Environ Int; 2024 Feb; 184():108493. PubMed ID: 38350257
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Epigenetic drug screening for trophoblast syncytialization reveals a novel role for MLL1 in regulating fetoplacental growth.
    Wu J; Qin C; Tian F; Liu X; Hu J; Wu F; Chen C; Lin Y
    BMC Med; 2024 Feb; 22(1):57. PubMed ID: 38317232
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. New genetic drivers in hemorrhagic hereditary telangiectasia.
    Cerdà P; Castillo SD; Aguilera C; Iriarte A; Rocamora JL; Larrinaga AM; Viñals F; Graupera M; Riera-Mestre A
    Eur J Intern Med; 2024 Jan; 119():99-108. PubMed ID: 37689549
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Promyelocytic leukemia protein regulates angiogenesis and epithelial-mesenchymal transition to limit metastasis in MDA-MB-231 breast cancer cells.
    Vogiatzoglou AP; Spanou S; Sachini N; Drakos E; Nikolaou C; Makatounakis T; Kretsovali A; Papamatheakis J
    Mol Oncol; 2023 Oct; 17(10):2090-2108. PubMed ID: 37518985
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Mechanism of Procyanidin B2 in the Treatment of Chronic Myeloid leukemia Based on Integrating Network Pharmacology and Molecular Docking.
    Li HX; Jing YX; Chai YH; Sun XH; He XX; Xue SL; Xi YM; Ma XL
    Anticancer Agents Med Chem; 2023; 23(16):1838-1847. PubMed ID: 37246327
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia.
    Gayatri MB; Kancha RK; Patchva D; Velugonda N; Gundeti S; Reddy ABM
    FEBS J; 2023 Sep; 290(18):4480-4495. PubMed ID: 37171230
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
    Wang X; Chen C; Vuong D; Rodriguez-Rodriguez S; Lam V; Roleder C; Wang JH; Thiruvengadam SK; Berger A; Pennock N; Torka P; Hernandez-Ilizaliturri F; Siddiqi T; Wang L; Xia Z; Danilov AV
    Leukemia; 2023 Jun; 37(6):1324-1335. PubMed ID: 37031300
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Connexin 43-modified bone marrow stromal cells reverse the imatinib resistance of K562 cells via Ca 2+ -dependent gap junction intercellular communication.
    Li X; Xiao Y; Wang X; Huang R; Wang R; Deng Y; Rao J; Gao Q; Yang S; Zhang X
    Chin Med J (Engl); 2023 Jan; 136(2):194-206. PubMed ID: 36801891
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 12.